
Scott D Lane

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4046395/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Electrophysiological responses to emotional and cocaine cues reveal individual neuroaffective profiles in cocaine users Experimental and Clinical Psychopharmacology, 2022, 30, 514-524.	1.8	8
2	Comorbid alcohol use and post-traumatic stress disorders: Pharmacotherapy with aldehyde dehydrogenase 2 inhibitors versus current agents. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 115, 110506.	4.8	2
3	Distress tolerance: prospective associations with cognitive-behavioral therapy outcomes in adults with posttraumatic stress and substance use disorders. Cognitive Behaviour Therapy, 2022, 51, 326-342.	3.5	7
4	Abstract TP206: Vascular Risk Factors And Stimulant Use Among Stroke Patients. Stroke, 2022, 53, .	2.0	0
5	Early pain, stress, and opioid use following traumatic injury. Journal of Opioid Management, 2022, 18, 17-25.	0.5	1
6	A metaâ€analysis of tractâ€based spatial statistics studies examining white matter integrity in cocaine use disorder. Addiction Biology, 2021, 26, e12902.	2.6	20
7	Plasma pro- and anti-inflammatory cytokines may relate to cocaine use, cognitive functioning, and depressive symptoms in cocaine use disorder. American Journal of Drug and Alcohol Abuse, 2021, 47, 52-64.	2.1	10
8	Dose-response effects of d-amphetamine on effort-based decision-making and reinforcement learning. Neuropsychopharmacology, 2021, 46, 1078-1085.	5.4	36
9	Cocaine-specific speed-accuracy trade-off during anti-saccade testing differentiates patients with cocaine use disorder who achieve initial abstinence during treatment. Journal of Psychopharmacology, 2021, 35, 611-614.	4.0	3
10	White matter deficits in cocaine use disorder: convergent evidence from in vivo diffusion tensor imaging and ex vivo proteomic analysis. Translational Psychiatry, 2021, 11, 252.	4.8	12
11	Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial. Nicotine and Tobacco Research, 2021, 23, 1682-1690.	2.6	21
12	Acute drug effects differentially predict desire to take dextroamphetamine again for work and recreation. Psychopharmacology, 2021, 238, 2815-2826.	3.1	1
13	The effects of combination levodopa-ropinirole on cognitive improvement and treatment outcome in individuals with cocaine use disorder: A bayesian mediation analysis. Drug and Alcohol Dependence, 2021, 225, 108800.	3.2	3
14	Posttraumatic stress symptom clusters differentially predict late positive potential to cocaine imagery cues in trauma-exposed adults with cocaine use disorder. Drug and Alcohol Dependence, 2021, 227, 108929.	3.2	3
15	Inpatient early intervention for serious mental illnesses and post-discharge criminal involvement in a high-volume psychiatric hospital setting. Journal of Psychiatric Research, 2021, 143, 285-291.	3.1	0
16	Citalopram for treatment of cocaine use disorder: A Bayesian drop-the-loser randomized clinical trial. Drug and Alcohol Dependence, 2021, 228, 109054.	3.2	7
17	Customizing Early Intervention Treatment for Psychosis in the UTHealth – Harris County Psychiatric Center. Inquiry (United States), 2021, 58, 004695802110490.	0.9	0
18	Targeting white matter neuroprotection as a relapse prevention strategy for treatment of cocaine use disorder: Design of a mechanism-focused randomized clinical trial. Contemporary Clinical Trials, 2021, 111, 106603.	1.8	0

#	Article	IF	CITATIONS
19	COVID-19 Vaccine Hesitancy in the Inpatient Psychiatric Setting. Psychiatric Services, 2021, 72, 1360-1361.	2.0	2
20	Analysis of COVID-19 Infection and Mortality Among Patients With Psychiatric Disorders, 2020. JAMA Network Open, 2021, 4, e2134969.	5.9	27
21	Preliminary examination of the orexin system on relapse-related factors in cocaine use disorder. Brain Research, 2020, 1731, 146359.	2.2	33
22	Equal response rates maintained by concurrent drug and nondrug reinforcers: a design for treatment evaluation. Behavioural Pharmacology, 2020, 31, 458-464.	1.7	0
23	Mindfulness as a predictor of cognitive-behavioral therapy outcomes in inner-city adults with posttraumatic stress and substance dependence. Addictive Behaviors, 2020, 104, 106283.	3.0	8
24	Elevated Neutrophil to Lymphocyte Ratio in Older Adults with Cocaine Use Disorder as a Marker of Chronic Inflammation. Clinical Psychopharmacology and Neuroscience, 2020, 18, 32-40.	2.0	21
25	Comment on "At-risk drinking and current cannabis use among medical students: a multivariable analysis of the role of personality traits― Revista Brasileira De Psiquiatria, 2020, 42, 122-123.	1.7	0
26	Predicting HCV Incidence in Latinos with High-Risk Substance Use: A Data Science Approach. Social Work in Public Health, 2019, 34, 606-615.	1.4	6
27	Measures of possible allostatic load in comorbid cocaine and alcohol use disorder: Brain white matter integrity, telomere length, and anti-saccade performance. PLoS ONE, 2019, 14, e0199729.	2.5	17
28	Regional differences in white matter integrity in stimulant use disorders: A meta-analysis of diffusion tensor imaging studies. Drug and Alcohol Dependence, 2019, 201, 29-37.	3.2	27
29	Baseline resting heart rate variability predicts postâ€traumatic stress disorder treatment outcomes in adults with coâ€occurring substance use disorders and postâ€traumatic stress. Psychophysiology, 2019, 56, e13377.	2.4	23
30	Resting Heart Rate Variability: Exploring Associations With Symptom Severity in Adults With Substance Use Disorders and Posttraumatic Stress. Journal of Dual Diagnosis, 2019, 15, 2-7.	1.2	13
31	Using a data science approach to predict cocaine use frequency from depressive symptoms. Drug and Alcohol Dependence, 2019, 194, 310-317.	3.2	4
32	Assessing attentional bias and inhibitory control in cannabis use disorder using an eye-tracking paradigm with personalized stimuli Experimental and Clinical Psychopharmacology, 2019, 27, 578-587.	1.8	7
33	Development of a novel, integrated cognitive-behavioral therapy for co-occurring posttraumatic stress and substance use disorders: A pilot randomized clinical trial. Contemporary Clinical Trials, 2018, 65, 123-129.	1.8	21
34	PPARÎ ³ agonism attenuates cocaine cue reactivity. Addiction Biology, 2018, 23, 55-68.	2.6	24
35	The impact of substance use disorders on clinical outcomes in olderâ€adult psychiatric inpatients. International Journal of Geriatric Psychiatry, 2018, 33, e323-e329.	2.7	4
36	Altered anterior cingulate cortex to hippocampus effective connectivity in response to drug cues in men with cocaine use disorder. Psychiatry Research - Neuroimaging, 2018, 271, 59-66.	1.8	17

#	Article	IF	CITATIONS
37	Differences in decision-making as a function of drug of choice. Pharmacology Biochemistry and Behavior, 2018, 164, 118-124.	2.9	25
38	Anhedonia in cocaine use disorder is associated with inflammatory gene expression. PLoS ONE, 2018, 13, e0207231.	2.5	12
39	A data science approach to predicting patient aggressive events in a psychiatric hospital. Psychiatry Research, 2018, 268, 217-222.	3.3	24
40	Genetic and Psychosocial Predictors of Aggression: Variable Selection and Model Building With Component-Wise Gradient Boosting. Frontiers in Behavioral Neuroscience, 2018, 12, 89.	2.0	11
41	Distress tolerance: Associations with trauma and substance cue reactivity in low-income, inner-city adults with substance use disorders and posttraumatic stress Psychology of Addictive Behaviors, 2018, 32, 264-276.	2.1	22
42	Immunology of Substance Use Disorders. , 2018, , 165-178.		1
43	PPARâ€gamma agonist pioglitazone modifies craving intensity and brain white matter integrity in patients with primary cocaine use disorder: a doubleâ€blind randomized controlled pilot trial. Addiction, 2017, 112, 1861-1868.	3.3	58
44	Anhedonia Is Associated with Poorer Outcomes in Contingency Management for Cocaine Use Disorder. Journal of Substance Abuse Treatment, 2017, 72, 32-39.	2.8	69
45	Heightened early-attentional stimulus orienting and impulsive action in men with antisocial personality disorder. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 697-707.	3.2	2
46	Reward vs. Retaliation—the Role of the Mesocorticolimbic Salience Network in Human Reactive Aggression. Frontiers in Behavioral Neuroscience, 2016, 10, 179.	2.0	21
47	Attentional bias in adults with cannabis use disorders. Journal of Addictive Diseases, 2016, 35, 144-153.	1.3	26
48	Neural correlates of impulsive aggressive behavior in subjects with a history of alcohol dependence Behavioral Neuroscience, 2015, 129, 183-196.	1.2	37
49	Anti-saccade error rates as a measure of attentional bias in cocaine dependent subjects. Behavioural Brain Research, 2015, 292, 493-499.	2.2	23
50	Inhibitory behavioral control: A stochastic dynamic causal modeling study comparing cocaine dependent subjects and controls. NeuroImage: Clinical, 2015, 7, 837-847.	2.7	37
51	Racial disparities during admission to an academic psychiatric hospital in a large urban area. Comprehensive Psychiatry, 2015, 63, 113-122.	3.1	21
52	Inhibitory Behavioral Control: A Stochastic Dynamic Causal Modeling Study Using Network Discovery Analysis. Brain Connectivity, 2015, 5, 177-186.	1.7	15
53	Trait impulsivity and increased pre-attentional sensitivity to intense stimuli in bipolar disorder and controls. Journal of Psychiatric Research, 2015, 60, 73-80.	3.1	5
54	Comparison of Caffeine and d-amphetamine in Cocaine-Dependent Subjects: Differential Outcomes on Subjective and Cardiovascular Effects, Reward Learning, and Salivary Paraxanthine. Journal of Addiction Research & Therapy, 2014, 05, 176.	0.2	11

#	Article	IF	CITATIONS
55	Antisocial personality disorder and borderline symptoms are differentially related to impulsivity and course of illness in bipolar disorder. Journal of Affective Disorders, 2013, 148, 384-390.	4.1	27
56	Pre-attentive information processing and impulsivity in bipolar disorder. Journal of Psychiatric Research, 2013, 47, 1917-1924.	3.1	22
57	Norepinephrine and impulsivity: effects of acute yohimbine. Psychopharmacology, 2013, 229, 83-94.	3.1	54
58	The role of cortisol and psychopathy in the cycle of violence. Psychopharmacology, 2013, 227, 661-672.	3.1	31
59	Effects of escitalopram on attentional bias to cocaine-related stimuli and inhibitory control in cocaine-dependent subjects. Journal of Psychopharmacology, 2013, 27, 801-807.	4.0	10
60	Chronic tiagabine administration and aggressive responding in individuals with a history of substance abuse and antisocial behavior. Journal of Psychopharmacology, 2012, 26, 982-993.	4.0	6
61	Differential relationships of impulsivity or antisocial symptoms on P50, N100, orÂP200 auditory sensory gating in controls and antisocial personality disorder. Journal of Psychiatric Research, 2012, 46, 743-750.	3.1	28
62	Neuropsychiatry of Aggression. Neurologic Clinics, 2011, 29, 49-64.	1.8	41
63	Criminal conviction, impulsivity, and course of illness in bipolar disorder. Bipolar Disorders, 2011, 13, 173-181.	1.9	36
64	Interacting mechanisms of impulsivity in bipolar disorder and antisocial personality disorder. Journal of Psychiatric Research, 2011, 45, 1477-1482.	3.1	22
65	Neural substrates of time perception and impulsivity. Brain Research, 2011, 1406, 43-58.	2.2	88
66	Now or later? Striatum and insula activation to immediate versus delayed rewards Journal of Neuroscience, Psychology, and Economics, 2010, 3, 15-26.	1.0	68
67	Zolmitriptan and human aggression: interaction with alcohol. Psychopharmacology, 2010, 210, 521-531.	3.1	25
68	Relationship between impulsivity and decision making in cocaine dependence. Psychiatry Research, 2010, 178, 299-304.	3.3	94
69	Diffusion Tensor Imaging and Decision Making in Cocaine Dependence. PLoS ONE, 2010, 5, e11591.	2.5	91
70	Acute topiramate differentially affects human aggressive responding at low vs. moderate doses in subjects with histories of substance abuse and antisocial behavior. Pharmacology Biochemistry and Behavior, 2009, 92, 357-362.	2.9	18
71	Trait impulsivity and response inhibition in antisocial personality disorder. Journal of Psychiatric Research, 2009, 43, 1057-1063.	3.1	140
72	Severity of bipolar disorder is associated with impairment of response inhibition. Journal of Affective Disorders, 2009, 116, 30-36.	4.1	80

#	Article	IF	CITATIONS
73	Increased traitâ€like impulsivity and course of illness in bipolar disorder. Bipolar Disorders, 2009, 11, 280-288.	1.9	186
74	Diffusion tensor imaging in cocaine dependence: Regional effects of cocaine on corpus callosum and effect of cocaine administration route. Drug and Alcohol Dependence, 2009, 104, 262-267.	3.2	70
75	Baseline Neurocognitive Profiles Differentiate Abstainers and Non-Abstainers in a Cocaine Clinical Trial. Journal of Addictive Diseases, 2009, 28, 250-257.	1.3	35
76	GABAergic modulation of human social interaction in a prisoner's dilemma model by acute administration of alprazolam. Behavioural Pharmacology, 2009, 20, 657-661.	1.7	15
77	Modulation of human risky decision making by flunitrazepam. Psychopharmacology, 2008, 196, 177-188.	3.1	19
78	Effects of acute tiagabine administration on aggressive responses of adult male parolees. Journal of Psychopharmacology, 2008, 22, 144-152.	4.0	23
79	Performance of Cocaine Dependent Individuals and Controls on a Response Inhibition Task with Varying Levels of Difficulty. American Journal of Drug and Alcohol Abuse, 2007, 33, 717-726.	2.1	74
80	Response perseveration and adaptation in heavy marijuana-smoking adolescents. Addictive Behaviors, 2007, 32, 977-990.	3.0	68
81	Application of a computational decision model to examine acute drug effects on human risk taking Experimental and Clinical Psychopharmacology, 2006, 14, 254-264.	1.8	30
82	Effects of marijuana on temporal discriminations in humans. Behavioural Pharmacology, 2006, 17, 173-183.	1.7	13
83	Individual differences in drug abuse vulnerability: d-Amphetamine and sensation-seeking status. Psychopharmacology, 2006, 189, 17-25.	3.1	105
84	MARIJUANA EFFECTS ON HUMAN FORGETTING FUNCTIONS. Journal of the Experimental Analysis of Behavior, 2005, 83, 67-83.	1.1	43
85	Acute effects of alprazolam on risky decision making in humans. Psychopharmacology, 2005, 181, 364-373.	3.1	37
86	Acute Marijuana Effects on Human Risk Taking. Neuropsychopharmacology, 2005, 30, 800-809.	5.4	150
87	Performance of heavy marijuana-smoking adolescents on a laboratory measure of motivation. Addictive Behaviors, 2005, 30, 815-828.	3.0	52
88	Acute effects of gabapentin on laboratory measures of aggressive and escape responses of adult parolees with and without a history of conduct disorder. Psychopharmacology, 2004, 171, 405-412.	3.1	19
89	Alcohol effects on human risk taking. Psychopharmacology, 2004, 172, 68-77.	3.1	117
90	Acute marijuana effects on response–reinforcer relations under multiple variable-interval schedules. Behavioural Pharmacology, 2004, 15, 305-309.	1.7	10

#	Article	IF	CITATIONS
91	Selective activation of the nucleus accumbens during risk-taking decision making. NeuroReport, 2004, 15, 2123-2127.	1.2	137
92	Measurement of delay discounting using trial-by-trial consequences. Behavioural Processes, 2003, 64, 287-303.	1.1	67
93	Possible amotivational effects following marijuana smoking under laboratory conditions Experimental and Clinical Psychopharmacology, 2002, 10, 26-38.	1.8	36
94	Marijuana Effects on Sensitivity to Reinforcement in Humans. Neuropsychopharmacology, 2002, 26, 520-529.	5.4	24
95	Acute effects of baclofen, a γ-aminobutyric acid-B agonist, on laboratory measures of aggressive and escape responses of adult male parolees with and without a history of conduct disorder. Psychopharmacology, 2002, 164, 160-167.	3.1	18
96	Effects of chronic paroxetine administration on measures of aggressive and impulsive responses of adult males with a history of conduct disorder. Psychopharmacology, 2002, 159, 266-274.	3.1	92
97	Possible amotivational effects following marijuana smoking under laboratory conditions Experimental and Clinical Psychopharmacology, 2002, 10, 26-38.	1.8	18
98	Risk taking by adolescents with maladaptive behavior histories Experimental and Clinical Psychopharmacology, 2001, 9, 74-82.	1.8	24
99	Acute effects of D-fenfluramine on simultaneous measures of aggressive escape and impulsive responses of adult males with and without a history of conduct disorder. Psychopharmacology, 2001, 157, 221-227.	3.1	45
100	Risk Aversion in Human Subjects under Conditions of Probabilistic Reward. Psychological Record, 2000, 50, 221-234.	0.9	5
101	Laboratory and questionnaire measures of aggression among female parolees with violent or nonviolent histories. Aggressive Behavior, 2000, 26, 291-307.	2.4	30
102	Fenfluramine effects on impulsivity in a sample of adults with and without history of conduct disorder. Psychopharmacology, 2000, 152, 149-156.	3.1	35
103	Analysis of risk taking in adults with a history of high risk behavior. Drug and Alcohol Dependence, 2000, 60, 179-187.	3.2	57
104	Prolactin response to buspirone was reduced in violent compared to nonviolent parolees. Psychopharmacology, 1999, 142, 144-148.	3.1	22
105	Laboratory and psychometric measurements of impulsivity among violent and nonviolent female parolees. Biological Psychiatry, 1999, 46, 273-280.	1.3	59
106	Antisocial Personality Disorder and Alcoholâ€induced Aggression. Alcoholism: Clinical and Experimental Research, 1998, 22, 1898-1902.	2.4	62
107	Increasing the Generativity of Identity-Based Procedures for Establishing Arbitrary Conditional Relations. Psychological Record, 1998, 48, 457-479.	0.9	8
108	Aggressive Responding in the Laboratory Maintained by the Initiation of a Provocation-Free Interval. Psychological Record, 1998, 48, 591-600.	0.9	4

#	Article	IF	CITATIONS
109	Antisocial Personality Disorder and Alcohol-Induced Aggression. Alcoholism: Clinical and Experimental Research, 1998, 22, 1898.	2.4	18